Compare Johnson & Johnson (JNJ) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Medtronic PLC — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Johnson & Johnson is far larger — about 5.5× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Medtronic PLC for 63 Days on average.
| JNJ | MDT | |
|---|---|---|
Market Cap | $618.09B | $112.24B |
Volume | 6,050,983 | 105,663,236 |
Sector | Health | Health |
52-Week High | $278.43 | $105.35 |
52-Week Low | $186.00 | $73.75 |
Typical Hold Time | 129 Days | 63 Days |
Enterprise Value | $646.37B | $131.58B |
Dividend Yield | 2.09% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
